Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
102 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Genital Herpes - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Genital Herpes - Pipeline Review, H1 2017, provides an overview of the Genital Herpes (Infectious Disease) pipeline landscape. Genital herpes is a common sexually transmitted infection that affects both men and women. Genital herpes is caused by the herpes simplex virus (HSV). Symptoms include decreased appetite, fever, general sick feeling (malaise), muscle aches in the lower back, buttocks, thighs, or knees and swollen and tender lymph nodes in the groin during an outbreak. Treatment includes antiviral medications. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Genital Herpes - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Genital Herpes (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Genital Herpes (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Genital Herpes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 3, 18 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Genital Herpes (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Genital Herpes (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Genital Herpes (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Genital Herpes (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Genital Herpes (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Genital Herpes (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Genital Herpes (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Genital Herpes (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Genital Herpes - Overview Genital Herpes - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Genital Herpes - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Genital Herpes - Companies Involved in Therapeutics Development Abivax SA Admedus Ltd AiCuris GmbH & Co KG Biomere LLC Foamix Pharmaceuticals Ltd Genocea Biosciences Inc GenVec Inc Immune Design Corp JN-International Medical Corp N & N Pharmaceuticals Inc NanoBio Corp NanoViricides Inc Profectus BioSciences Inc Redbiotec AG Sanofi Pasteur SA Starpharma Holdings Ltd Tomegavax Inc Vaccibody AS Vaxart Inc Vical Inc Genital Herpes - Drug Profiles ABX-196 - Drug Profile Product Description Mechanism Of Action R&D Progress acyclovir - Drug Profile Product Description Mechanism Of Action R&D Progress Aspidasept - Drug Profile Product Description Mechanism Of Action R&D Progress astodrimer - Drug Profile Product Description Mechanism Of Action R&D Progress G-103 - Drug Profile Product Description Mechanism Of Action R&D Progress GEN-003 - Drug Profile Product Description Mechanism Of Action R&D Progress genital herpes (virus like particle) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress genital herpes vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress genital herpes vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress genital herpes vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress genital herpes vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress genital herpes vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress GV-2207 - Drug Profile Product Description Mechanism Of Action R&D Progress herpes simplex virus [type 1, 2] vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress herpes simplex virus 2 vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress herpes simplex virus 2 vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress herpes simplex virus 2 vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress herpes simplex virus 2 vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress herpes simplex virus 2 vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress HSV-529 - Drug Profile Product Description Mechanism Of Action R&D Progress NN-001 - Drug Profile Product Description Mechanism Of Action R&D Progress pritelivir - Drug Profile Product Description Mechanism Of Action R&D Progress Profavax HSV-1 - Drug Profile Product Description Mechanism Of Action R&D Progress Profavax HSV-2 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule for Genital Herpes - Drug Profile Product Description Mechanism Of Action R&D Progress Theravax HSV-1 - Drug Profile Product Description Mechanism Of Action R&D Progress Theravax HSV-2 - Drug Profile Product Description Mechanism Of Action R&D Progress VCLHB-01 - Drug Profile Product Description Mechanism Of Action R&D Progress VCLHM-01 - Drug Profile Product Description Mechanism Of Action R&D Progress VTMX-004 - Drug Profile Product Description Mechanism Of Action R&D Progress Genital Herpes - Dormant Projects Genital Herpes - Discontinued Products Genital Herpes - Product Development Milestones Featured News & Press Releases Mar 06, 2017: NanoBio Receives SBIR Grant For Genital Herpes Vaccine Jan 05, 2017: Genocea Announces Positive 6-Month Results from GEN-003 Phase 2b Clinical Trial Dec 14, 2016: Genocea R&D Day Highlighted Lead Program, GEN-003, for the Treatment of Genital Herpes and Introduced Immuno-Oncology Programs & Strategy Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes Oct 28, 2016: Genocea Presents New 12 month Data on Genital Herpes Immunotherapy GEN-003 at IDWeek 2016 Oct 19, 2016: Admedus Announces Positive Unblinded HSV-2 Phase II Interim Data Sep 29, 2016: Genocea's Genital Herpes Immunotherapy GEN-003 Demonstrates Significant Reduction of Viral Shedding in Phase 2b Clinical Trial Jun 20, 2016: A novel therapy for genital herpes engages immune cells to provide significant patient benefits Jun 20, 2016: Vicals Phase 1/2 Trial Data Presented at ASM 2016 Shows Bivalent Vaccine Imparts Reduction in Genital Herpes Lesions Durable to 9 Months Jun 09, 2016: Genocea Showcases Potential of Genital Herpes Immunotherapy GEN-003 at ASM Microbe 2016 Mar 31, 2016: Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 Months Post-Dosing Mar 04, 2016: Interim HSV-2 Phase II clinical trial data encouraging Feb 03, 2016: Model helps decide drug dose for clinical testing Jan 29, 2016: Genocea Commences Dosing in Phase 2b Study for Genital Herpes Treatment, GEN-003 Oct 07, 2015: Genocea Announces Positive Durability Data from 6-Month Analysis of Phase 2 Clinical Trial of Genital Herpes Immunotherapy GEN-003 Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Genital Herpes, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Genital Herpes - Pipeline by Abivax SA, H1 2017 Genital Herpes - Pipeline by Admedus Ltd, H1 2017 Genital Herpes - Pipeline by AiCuris GmbH & Co KG, H1 2017 Genital Herpes - Pipeline by Biomere LLC, H1 2017 Genital Herpes - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017 Genital Herpes - Pipeline by Genocea Biosciences Inc, H1 2017 Genital Herpes - Pipeline by GenVec Inc, H1 2017 Genital Herpes - Pipeline by Immune Design Corp, H1 2017 Genital Herpes - Pipeline by JN-International Medical Corp, H1 2017 Genital Herpes - Pipeline by N & N Pharmaceuticals Inc, H1 2017 Genital Herpes - Pipeline by NanoBio Corp, H1 2017 Genital Herpes - Pipeline by NanoViricides Inc, H1 2017 Genital Herpes - Pipeline by Profectus BioSciences Inc, H1 2017 Genital Herpes - Pipeline by Redbiotec AG, H1 2017 Genital Herpes - Pipeline by Sanofi Pasteur SA, H1 2017 Genital Herpes - Pipeline by Starpharma Holdings Ltd, H1 2017 Genital Herpes - Pipeline by Tomegavax Inc, H1 2017 Genital Herpes - Pipeline by Vaccibody AS, H1 2017 Genital Herpes - Pipeline by Vaxart Inc, H1 2017 Genital Herpes - Pipeline by Vical Inc, H1 2017 Genital Herpes - Dormant Projects, H1 2017 Genital Herpes - Dormant Projects, H1 2017 (Contd..1), H1 2017 Genital Herpes - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
